Bush Budget Would Reduce Number Of New NIH Grants

Sidebar: Wrong Number, Please Try Again The president's request for 1993 specifies more science support overall but dims hopes for some individual researchers WASHINGTON--On the surface, the 1993 budget that President Bush submitted to Congress January 29 should look very familiar to researchers: A lot more for the National Science Foundation, a little more for the National Institutes of Health, and large increases to pay for the continuing construction of the superconducting supercollider an

Written byJeffrey Mervis
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Sidebar: Wrong Number, Please Try Again

But the $1.5 trillion budget request that Congress will soon dissect and rearrange contains some unpleasant surprises for the scientific community. Many agencywide increases are accompanied by cuts in programs that many scientists hold dear, suggesting a showdown later in the year.

One notable example is the proposed $9.37 billion budget for NIH. While 5 percent higher than in 1992, the Bush budget will fund 200 fewer new and competing research project grants than in the current fiscal year. That level--5,797-- not only will increase the already fierce competition for NIH grants among individual investigators, but also flouts the congressional instruction to NIH that it fund at least 6,000 such grants annually.

NIH director Bernadine Healy has warned scientists repeatedly not to use a particular number as a yardstick of the health of NIH's budget. "If R01s [NIH's label for individual investigator-initiated grants] are ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies